Inhibrx Biosciences, Inc. INBX Business Segments — Merger-related
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inbx:GeneralAndAdministrativeExpenseMergerRelated.
The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — merger-related.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — merger-related?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — merger-related of $0 in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s business segments — merger-related changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — merger-related decreased by 100.0% year-over-year, from $17.02M to $0.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — merger-related?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — merger-related has grown at a -100.0% compound annual growth rate (CAGR), from $36K to $0.
- What does business segments — merger-related mean?
- Represents non-recurring costs directly attributable to merger, acquisition, or corporate restructuring activities within the segment. Monitoring this metric helps investors distinguish between core operational performance and one-time transaction-related financial impacts.